Straits Times Index
3,439.88 +24.37 (+0.71%) S&P 500
5,537.02 +28.01 (+0.51%) Dow
39,308.00 -23.90 (-0.06%) Nasdaq
18,188.30 +159.54 (+0.88%) Bitcoin USD
57,938.35 -2,567.31 (-4.24%) CMC Crypto 200
1,208.71 -52.48 (-4.16%)
REGN Jul 2024 1035.000 put
- Benzinga
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils. Specifically, the approval covers patients already on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) or on a combination of LABA and LAMA if ICS is not appropriate. Sanofi SA (NASDAQ
- Zacks
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.
- Reuters
EU approves Sanofi's Dupixent for 'smoker's lungs'
The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a recommendation by the European Medicines Agency (EMA) at the end of May. The debilitating disease is also known as 'smoker's lungs' because in western countries it primarily affects cigarette smokers.
